Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B-Clear phase IIb study of bepirovirsen in chronic hepatitis B
2020-001083-29Phase 2Completed
- Sponsor
- GSK
- Start
- May 2020
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of bepirovirsen in Chronic Hepatitis B (CHB) (3 arms), sponsored by GSK. Primary endpoint: Primary efficacy estimands. Started May 2020; status: completed.
02
Drugs
bepirovirsen
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2020-001083-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001083-29.